Because TB-500 is often overexpressed in malignant cells and facilitates angiogenesis, there is a theoretical risk that it could accelerate the growth of dormant tumors or increase metastatic capacity in certain cancer phenotypes
The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
100% fees at risk* 0% GLP-1 for weight loss trend guarantee 8% bodyweight reduction, with or without GLP-1 medications More than just marketing claims, validated weight loss results Years of nutrition-first care, medication management, and GLP-1 deprescription when clinically appropriate Learn about our approach Weight loss without drugs View our outcomes Sustained weight loss a year after GLP-1 deprescription See the results How it works Easy implementation via PBM integrations enables guardrails without rebate impact Navigate members to Virtas effective care via our PBM integrations and member communications Educate on the benefits of Nutrition Therapy and guide each member to the right care with or without GLP-1s Adapt nutrition and behavioral care to each member based on lifestyle, metabolism, and continuous health data Maximize success for those on GLP-1s with provider-led effective titration, side-effect support, and engagement monitoringno wasted spend on off-label prescriptions or ineffective anti-obesity medications
Sophie Shotter for bespoke protocols which may include topical treatments, oral medications, supplements, or lifestyle adjustments
NNMT-related research is relevant to models involving adipocyte biology, NAD+-associated pathways, methylation-linked metabolism, and cellular energy regulation
European Heart Journal - Cardiovascular Pharmacotherapy 10(4):296306 Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
:max_bytes(150000):strip_icc()/VWH-Zepbound-a91ec7a305e8407d83daa7b41039b4aa.jpg)
